ASEAN Harmonisation: What the ACD Cosmetic Directive and AHWP Medical Device Coordination Mean for Malaysia

To reduce technical barriers to trade within the region, ASEAN has spent years driving regulatory harmonisation across industries: the ASEAN Cosmetic Directive (ACD) for cosmetics, the ASEAN Medical Device Directive (AMDD) and the AHWP/GHWP coordination mechanism for medical devices, and the ACTD/ACTR common technical documents for pharmaceuticals. For brands looking to expand across multiple ASEAN countries, the biggest value of understanding this framework is that technical document formats are common, so one dossier can be reused across countries—there is no need to prepare from scratch in each market. Using Malaysia as the anchor, this article explains exactly what these harmonisation mechanisms have harmonised, and what they have not.

Cosmetics: the ASEAN Cosmetic Directive (ACD)

The ACD is the core of ASEAN cosmetic harmonisation. In 2003 ASEAN member states agreed to harmonise cosmetic requirements; the new regime took effect in 2008, and from 1 January 2008 Malaysia moved to a notification system—administered by the NPRA through the Quest3+ system, with no more case-by-case "registration."

What the ACD harmonises includes:

• Common definitions and ingredient annexes: the permitted / restricted / prohibited ingredient lists (Annexes) are adopted consistently across countries. Malaysia's NPRA updates these annexes by Circular in line with resolutions of the ASEAN Cosmetic Committee (ACC).
• Product Information File (PIF): safety assessment, formulation, GMP and other technical data follow a common structure.
• Labelling and claim principles: claims must not mislead and must not imply therapeutic effect.

Practical meaning: a cosmetic PIF and ingredient-compliance assessment prepared in Malaysia share a common overall structure when carried over to other ACD member states such as Thailand, Indonesia and Vietnam—only the differences in each country's notification system and language need to be handled. But note—notification is still done country by country. The ACD unifies the "rules," not "one notification valid across all of ASEAN."

Medical devices: AMDD and AHWP/GHWP

For medical devices there are two layers to keep clear:

1. AMDD (ASEAN Medical Device Directive): the ASEAN-level device directive, using a four-tier A/B/C/D risk classification (aligned with the EU and GHTF frameworks) and the CSDT (Common Submission Dossier Template). In Malaysia, this falls under the MDA pursuant to the Medical Device Act 2012 (Act 737), with classification and CSDT aligned to the AMDD; everything above Class A requires a CSDT technical file.
2. AHWP / GHWP: the AHWP (Asian Harmonization Working Party) is a broader international coordination body whose membership spans Asia, the Middle East, Africa and South America, and which is an affiliate of IMDRF; in recent years it has been renamed GHWP (Global Harmonization Working Party). It drives global-level device regulatory coordination and reference documents, and the AMDD and national regimes are largely influenced by it and by GHTF/IMDRF guidance.

Practical meaning: a device technical file that meets CSDT has a common format across AMDD member states such as Malaysia, Singapore and Thailand; if the original manufacturer already holds technical data under the IMDRF/GHWP framework, conversion costs are lower. But registration is still filed country by country, and each country requires a local Authorised Representative (AR).

Pharmaceuticals and health products: ACTD / ACTR

On the pharmaceutical side, the ASEAN Common Technical Dossier (ACTD) and ASEAN Common Technical Requirements (ACTR) bring the data format for drug registration into closer alignment across ASEAN. Malaysia's traditional medicines, health products and pharmaceuticals are handled by the NPRA under this type of framework. For regional expansion this again follows the logic of "data can be reused, but the process is still country by country."

How far does harmonisation go? One table to understand it

The most common misconception: assuming that "ASEAN harmonisation = one approval valid region-wide." The correct understanding is that harmonisation unifies technical standards and document formats, greatly reducing rework; but market approval is still gatekept one country at a time by each national authority, each of which also requires its own local holder / representative.

Three practical takeaways for brands

1. Build one high-quality master technical file first (PIF/CSDT/ACTD), then fine-tune per country, saving substantial duplicated cost.
2. Watch annex updates closely: ACD ingredient annexes change with ACC resolutions, implemented in Malaysia via NPRA Circulars, so formulations must be re-checked in step.
3. You need a local partner in every country: harmonisation does not exempt you from a local representative—the CNH, PRH and AR remain mandatory in each country.

Frequently asked questions (FAQ)

Q: After ACD notification, can I sell directly to all ASEAN countries? No. The ACD unifies ingredient annexes, PIF format and claim principles, but notification must still be done country by country. Malaysia's Quest3+ notification is only valid in Malaysia; Thailand, Indonesia and others each require their own notification.

Q: What is the difference between AHWP and AMDD? The AMDD is the ASEAN-level device directive (four-tier classification + CSDT); AHWP (now GHWP) is a broader international coordination body, an IMDRF affiliate, driving global device regulatory coordination. The former is a regional set of rules, the latter a coordination platform.

Q: I have an EU CE device technical file—can I reuse it in Malaysia? CE certification itself is not automatically recognised in Malaysia, but its technical data can be converted into CSDT format to support MDA registration, greatly reducing rework. Registration still requires a local Authorised Representative (AR).

Q: How often are cosmetic ingredient annexes updated? Irregularly. After the ASEAN Cosmetic Committee (ACC) meets and resolves, Malaysia's NPRA updates the permitted / prohibited lists in step via Circulars, and brands should regularly check whether their formulations are affected.

Q: What are the benefits of the harmonisation framework for smaller brands? The biggest benefit is "one master technical file, reused across countries," reducing document rework for cross-border expansion; but you still need to arrange a local holder and a country-by-country application for each target market.

Self-check checklist

• [ ] Built one high-quality master technical file (cosmetic PIF / device CSDT / pharmaceutical ACTD)
• [ ] Checked formulations against the ACD annexes and tracked NPRA Circular updates
• [ ] For devices, confirmed the AMDD risk classification (A/B/C/D) and CSDT completeness
• [ ] Arranged a local holder / authorised representative for each target country
• [ ] Did not mistake "harmonisation" for "one approval valid region-wide"

Conclusion

The essence of ASEAN harmonisation (ACD, AMDD/AHWP, ACTD) is unified standards, shared documents, country-by-country approval. Use it well and you can enter multiple countries on a single technical file and avoid many detours; misunderstand it and you will assume one notification opens the whole region and step on a landmine. Treating Malaysia as the first stop in your ASEAN strategy makes sense precisely because its NPRA and MDA regimes are so closely aligned with this harmonisation framework.

Want to quickly confirm whether your product label meets Malaysian requirements?

Run a free label check now

This article is compiled from official sources for reference only; actual compliance is subject to the latest official texts and reviews of the competent authorities.

Further reading: Malaysia market-entry roadmap, Importing China products into Malaysia, Imported cosmetics CNH notification holder, Imported health supplement PRH registration holder.